Novartis Spends $1.2M to Buy Additional Alnylam Shares as Part of Companies' 2005 Alliance | GenomeWeb

Alnylam Pharmaceuticals has pocketed around $1.2 million after Novartis fully exercised its right to purchase an additional 65,922 unregistered shares of Alnylam's common stock, pursuant to the companies' 2005 drug-discovery and -development deal, Novartis said this week.

Novartis, which Alnylam lists as its second biggest shareholder, said its decision to purchase the additional stock, for which it paid $17.50 per share, allows it to maintain its current 13.4 percent stake in Alnylam.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.